仑伐替尼或凡德他尼治疗中出现的原发性肾上腺功能不全及醋酸可的松改善疲劳
该研究评估了12例接受仑伐替尼或凡德他尼治疗的晚期放射性碘难治性分化型甲状腺癌(RAI-R DTC)和甲状腺髓样癌(MTC)患者的肾上腺功能。10例主诉疲劳的患者促肾上腺皮质激素(ACTH)进行性升高而皮质醇水平正常,其中6例ACTH兴奋后皮质醇反应迟钝,确诊原发性肾上腺功能不全(PAI)。PAI患者接受醋酸可的松替代治疗后疲劳显著且迅速改善,提示PAI可能是此类酪氨酸激酶抑制剂(TKI)治疗中疲劳的常见原因。
要点
- 接受仑伐替尼或凡德他尼治疗的患者出现疲劳时应检测肾上腺功能。
- 10例疲劳患者中6例ACTH兴奋后皮质醇反应迟钝,确诊原发性肾上腺功能不全。
- 确诊PAI后予醋酸可的松替代治疗可迅速改善疲劳,避免停药或减量。
核心结论
- 仑伐替尼和凡德他尼治疗期间发生的原发性肾上腺功能不全可能是疲劳的常见原因。
- 建议检测肾上腺功能以便及时启动替代治疗,避免停药、减量及潜在的严重PAI并发症。
研究设计与样本
- 评估了12例接受仑伐替尼或凡德他尼治疗的晚期RAI-R DTC和MTC患者的基线与刺激后肾上腺功能。
- 通过治疗前后重复检测肾上腺功能来论证TKI与PAI发病的因果关系。
主要发现
- 10例主诉疲劳的患者ACTH进行性升高而皮质醇水平正常。
- 10例中6例ACTH兴奋后皮质醇反应迟钝,确诊原发性肾上腺功能不全。
- PAI患者接受醋酸可的松替代治疗后疲劳程度显著且迅速改善,采用CTCAE 4.03版评估。
关键数值与推荐
- 10例疲劳患者中6例ACTH兴奋后皮质醇反应迟钝,确诊PAI。
- 疲劳改善程度按常见不良事件评价标准(CTCAE)4.03版评估。
临床怎么用
- 对接受仑伐替尼或凡德他尼治疗并出现疲劳的患者检测肾上腺功能。
- 确诊PAI后及时启动醋酸可的松替代治疗,以减少停药或减量及严重PAI并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Two tyrosine kinase inhibitors (TKIs), lenvatinib and vandetanib, are often used to treat advanced radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) and medullary thyroid cancer (MTC), respectively. Fatigue is a common adverse event during treatment with these and other TKIs and a common cause of drug discontinuation or dosage reduction. CASES DESCRIPTION: We evaluated the basal and stimulated adrenal function in 12 patients with advanced RAI-R DTC and MTC treated with lenvatinib or vandetanib, respectively. Ten patients complaining of fatigue showed a progressive ACTH increase with normal cortisol levels. Moreover, six of 10 patients had a blunted cortisol response after ACTH stimulation, thus confirming the diagnosis of primary adrenal insufficiency (PAI). The causal relationship between TKIs and PAI onset was also demonstrated by the repeated testing of adrenal function before and during treatment. Patients with PAI received cortisone acetate replacement therapy, with a substantial and prompt improvement in the degree of fatigue, as assessed by the Common Terminology Criteria for Adverse Events version 4.03, thus supporting the major impact of impaired adrenal function in the genesis of this adverse event. CONCLUSIONS: We show that the occurrence of PAI may be a common cause of fatigue during lenvatinib and vandetanib treatment, and we therefore recommend testing adrenal function for a prompt start of replacement therapy to avoid treatment discontinuation, dosage reduction, and potentially severe PAI complications.
引用
- Colombo C, De Leo S, Di Stefano M, et al. Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy. J Clin Endocrinol Metab. 2019. PMID: 30383218. doi:10.1210/jc.2018-01836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。